Esmya licensed for intermittent fibroid treatment

Esmya (ulipristal acetate) can now be used intermittently to treat moderate to severe symptoms of fibroids in women of reproductive age, providing an option for long-term medical management of the condition.

Esmya was previously only licensed for pre-operative use in the treatment of fibroids.
Esmya was previously only licensed for pre-operative use in the treatment of fibroids.

Intermittent treatment with Esmya involves patients taking one 5mg tablet daily for up to 3 months, starting during the first week of menstruation. In studies, intermittent treatment was evaluated for up to four 3-month courses.

Periodic monitoring of the endometrium is recommended in patients treated intermittently with Esmya. This should take place during a treatment off-period after menstruation has resumed. Monitoring should include an annual ultrasound and, if endometrial thickening is observed, a biopsy should be performed to rule out endometrial malignancy.

Further information
View Esmya drug record 
Summary of Product Characteristics
Manufacturer: Gedeon Richter UK

Ulipristal acetate usually leads to a significant reduction in menstrual blood loss or amenorrhoea within the first 10 days of treatment. A biopsy is recommended if any unexpected bleeding or an altered bleeding pattern is subsequently experienced.

Two phase III studies assessed use of ulipristal acetate for up to four intermittent 3-month treatment courses in patients with heavy menstrual bleeding associated with uterine fibroids.  

Reduced menstrual bleeding

PEARL III was an open-label study evaluating ulipristal acetate 10mg once daily, in which each 3-month treatment period was followed by 10 days of double-blind treatment with norethisterone acetate or placebo. In this study, efficacy was shown for up to 18 months of intermittent treatment, with 79.5% of women (105 of 132) in amenorrhoea (primary endpoint) after the first treatment course and 89.7% (96 of 107) in amenorrhoea at the end of the fourth treatment course.

PEARL IV was a randomised, double-blind study assessing ulipristal acetate 5mg or 10mg in 451 women. In total, 61.9% of patients in the 5mg group and 72.7% of those in the 10mg group were in amenorrhoea at the end of both treatment courses 1 and 2 (p=0.032); 48.7% and 60.5%, respectively, were in amenorrhoea at the end of all four treatment courses (p=0.027). After four treatment courses, there was no significant difference in the frequency of amenorrhoea between the two dose groups (p=0.290).

Both dose regimens of ulipristal acetate effectively controlled menorrhagia, with 81.1% of patients on the 5mg dose achieving controlled bleeding (as defined by no episodes of heavy bleeding and a maximum of 8 days of bleeding during the last 56 days of a treatment course) at the end of two treatment courses.

After the second treatment course, fibroid volume (based on the three largest fibroids) was reduced by a median of 54.1% and 58.0% in the patients receiving ulipristal acetate 5mg and 10mg, respectively (p=0.06). Patients also reported substantial improvements in pain and quality of life during treatment, and these improvements were partly maintained during the off-treatment period.

The investigators concluded that the 5mg dose of ulipristal acetate approved for pre-operative use would be appropriate for long-term symptom management.

Endometrial hyperplasia

In all phase III studies of ulipristal acetate in the treatment of fibroids, a total of 7 cases of hyperplasia were observed out of 789 patients with adequate biopsies (0.89%). Most of these spontaneously reverted to normal endometrium after resumption of menstruation during the off-treatment period. The incidence of hyperplasia in patients treated with ulipristal acetate is consistent with that in symptomatic pre-menopausal women and did not increase with repeated treatment courses. 

Well tolerated

Intermittent treatment with ulipristal acetate was generally well tolerated. The most frequent adverse reactions were hot flush, headache, nasopharyngitis and abdominal pain.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.